Xiang Ling
China Pharmaceutical University
8 Papers
21 Citations
Xiang Ling is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Drug carrier & Supply chain. The author has an hindex of 6, co-authored 6 publications. Previous affiliations of Xiang Ling include Brigham and Women's Hospital.
Chat about Author
Papers
Tumor-targeting delivery of hyaluronic acid–platinum(IV) nanoconjugate to reduce toxicity and improve survival
Xiang Ling,Yan Shen,Runing Sun,Mengze Zhang,Chang Li,Jinyin Mao,Jing Xing,Chunmeng Sun,Jiasheng Tu +8 more
TL;DR: A tumor-targeting HA-EDA–Pt(IV) nanoconjugate with reduced adverse reactions and enhanced efficacy is expected to overcome the bottleneck of present platinum drugs and holds great potential in clinical application for cancer therapy.
46
Development of an itraconazole encapsulated polymeric nanoparticle platform for effective antifungal therapy
Xiang Ling,Xiang Ling,Zewei Huang,Jianzhao Wang,Jiarong Xie,Feng Min,Yang Chen,Farhana Abbas,Jiasheng Tu,Jun Wu,Chunmeng Sun +10 more
TL;DR: The developed ITZ-NPs could reduce systemic toxicity, improve antifungal activity and act as a potential intravenous formulation of ITZ, indicating much better biocompatibility than marketed cyclodextrin formulations ofITZ.
46
Formulation and evaluation of Cyclosporin A emulgel for ocular delivery.
TL;DR: The polycarbophil-based emulgel could be exploited as a potential hydrophobic drug carrier for topical ocular drug delivery.
42
Synthesis and characterization of hyaluronic acid–platinum(IV) nanoconjugate with enhanced antitumor response and reduced adverse effects
TL;DR: The concise design of the nanoconjugate offers a simple way to overcome the toxicity and non-selectivity of cisplatin, which could improve therapeutical outcomes of platinum drugs in cancer therapy.
26
Risk assessment of supply chain for pharmaceutical excipients with AHP-fuzzy comprehensive evaluation.
TL;DR: It was concluded that polysorbate 80 for injection use is a high-risk ingredient in the supply chain compared to that for oral use to achieve safety application in clinic, thus measures should be taken to control and minimize those risks.